Abstract
We used [99mTc]EHIDA hepatobiliary scintigraphy to determine whether both hepatic bile secretion and gallbladder contractility are suppressed in acromegalic patients receiving long-term treatment with the somatostatin analogue octreotide. We studied three groups of patients: group 1, untreated patients; group 2, average dose of octreotide 500±100 µg/day for 33±4 months; and group 3, 1000±200 µg/day for 33±4 months. Images were taken at specified time intervals during the 120-min period following injection of EHIDA. After a single injection of octreotide, group 1 patients demonstrated delayed visualization of the radioisotope in the liver, gallbladder, and duodenum. At the end of long-term treatment, group 2 patients showed a delay in appearance of maximal radioactivity in the gallbladder. Two weeks following discontinuation of octreotide, this parameter had decreased significantly (P<0.001). In group 3, visualization of the liver, gallbladder, and duodenum were prolonged, with delayed visualization of the gallbladder persisting two weeks after withdrawal (P<0.005). These results indicate that gallbladder contractility is decreased after a single injection of octreotide and that during chronic octreotide therapy the rate of bile secretion is reduced. Impaired gallbladder contractility normalizes more rapidly after discontinuation of octreotide in patients receiving low doses of the analog.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Vance ML, Harris AG: Chronic somatostatin analog, octreotide (SMS 201–995), treatment of 189 acromegalic patients/results of the SMS 201–995 International Multicenter Acromegaly Study Group. Arch Intern Med 151:1573–1578, 1991
Ho KY, Weissberger AJ, Marbach P, Lazarus L: Therapeutic efficacy of the somatostatin analogue SMS 201–995 (octreotide) in acromegaly. Ann Intern Med 112:173–181, 1990
Lamberts SWJ: The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of its analogues in the treatment of human pituitary tumors. Endocrinol Rev 9:417–436, 1988
Shi YF, Harris AG, Zhu XF, Deng JY: Clinical and biochemical effects of incremental doses of the long-acting somatostatin analogue SMS 201–995 in ten acromegalic patients. Clin Endocrinol 32:695–705, 1990
McKnight JA, McCance DR, Atkinson AB, Crothers JG: Changes in glucose tolerance and development of gallstone during high dose treatment with octreotide for acromegaly. Br Med J 299:604, 1989
Shi YF, Zhu XF, Harris AG, Zhang JX, Dai Q, Deng JE: Prospective study of the long-term effects of somatostatin analogue (octreotide) on gallbladder function and gallstone formation in Chinese acromegalic patients. J Clin Endocrinol Metab 76:32–37, 1993
Everson GT, Braverman DZ, Johnson ML, Kern F: A critical evaluation of real-time ultrasonography for the study gallbladder volume and contraction. Gastroenterology. 79:40–46, 1980
Zhou Qian, Jiang Zhu-ming, Yang Mei-fang, Xu Jing-yin and Zhang Fusen. Evaluation of function of hepatobiliary system examined by EHIDA hepatobiliary imaging in patients on parenteral nutrition. China Natl J Nucl Med 8:195–198, 1988
Weismann HS, Badia JD, Hall T: Tc-99m diisopropyl iminodiacetic acid: The best overall cholescintigraphic radionuclide for the evaluation of hepatobiliary disorders. J Nucl Med 21:18, 1980
Marteau P, Chretien Y, Calmus Y, Parc R, Poupon R: Pharmacological effects of somatostatin on bile secretion in man. Digestion 42:16–21, 1989
Lembcke B, Creutzfeldt W, Schleser S, Ebert R, Shaw C, Koop I: Effect of the somatostatin analogue Sandostatin (SMS 201–995) on gastrointestinal, pancreatic and biliary tract function and hormone release in normal men. Digestion 36:108–124, 1987
Marbach P, Andres H, Azria M: Chemical structure, pharmacodynamic profile and pharmacokinetics of SMS 201–995.In Sandostatin in the Treatment of Acromegaly. SWJ Lamberts (ed). Berlin, Springer-Verlag, 1988, pp 50–60
Kutz K, Nüesch E, Rosenthaler J: Pharmacokinetics of SMS 201–995 in healthy subjects. Scand J Gastroenterol, 119(suppl 21):65–72, 1986
Longnecker SM: Somatostatin and octreotide: Literature review and description of therapeutic activity in pancreatic neoplasia. Drug Intell Clin Pharmacol 22:99–106, 1988
Ricci GL, Fevery J: Cholestatic action of somatostatin in the rat effect of the different fractions of bile secretion. Gastroenterology 81:552–562, 1981
Arilla E, Colas B, Prieto JC: Specific somatostatin-binding to cytosol of bovine gallbladder mucosa. Biosci Rep 6:283–291, 1986
Arimura A, Sato H, Dupont A, Nishi N, Schally AV: Somatostatin: Abundance of immunoreactive hormone in rat stomach and pancreas. Science 189:1007–1009, 1975
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Zhu, XF., Harris, A.G., Yang, M.F. et al. Effect of octreotide on dynamic excretion of bile in Chinese acromegalic patients assessed by [99mTc]EHIDA hepatobiliary scan. Digest Dis Sci 39, 284–288 (1994). https://doi.org/10.1007/BF02090198
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02090198